特朗普称将对进口药品征收“小额关税”；国家医保局发布第十一批药品集采填报情况 | 医药早参

Group 1 - The U.S. President Trump announced plans to impose a "small tariff" on imported pharmaceuticals, which could increase to 150% within a year and potentially reach 250% thereafter, aiming to encourage domestic production [1] - The National Healthcare Security Administration of China reported that 480 companies submitted information for the 11th batch of drug procurement, with an average of 15 companies per drug, indicating significant competition in the market [2] - Dongyang Sunshine Pharmaceutical voluntarily withdrew its H-share listing status in Hong Kong as part of a privatization plan, which is expected to enhance its operational efficiency and market performance post-merger [3] Group 2 - Yibai Pharmaceutical received a suspension notice from the Guizhou Provincial Drug Administration due to compliance issues, which may impact market confidence despite the company stating it won't significantly affect performance [4] - Lianhuan Pharmaceutical responded to an inquiry regarding unusual stock price fluctuations, asserting that there are no undisclosed significant matters affecting its stock price, which may help stabilize market expectations [5]